Eur Rev Med Pharmacol Sci 2022; 26 (4): 1070-1072
DOI: 10.26355/eurrev_202202_28094

Can the cardioprotective effect of microRNA-103 inhibitors be extended to women with polycystic ovary syndrome?

P. Ramaswamy, M.K. Sibin, P. Misra, R. Sahu

Multidisciplinary Research Unit (MRU), Armed Forces Medical College, Maharashtra, India. palani.swamy20@gmail.com

Free PDF Download

To cite this article

P. Ramaswamy, M.K. Sibin, P. Misra, R. Sahu
Can the cardioprotective effect of microRNA-103 inhibitors be extended to women with polycystic ovary syndrome?

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 4
Pages: 1070-1072
DOI: 10.26355/eurrev_202202_28094

Keywords Related articles:

  1. The association between knee osteoarthritis and polycystic ovary syndrome in postmenopausal women: preliminary results
  2. Effect of microRNA-409 on the pathogenesis of polycystic ovary syndrome
  3. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial
  4. Increased epicardial fat thickness is related with body mass index in women with polycystic ovary syndrome
  5. The correlation between the concentration of hepcidin in serum and the occurrence of insulin resistance and hyperandrogenemia in women with polycystic ovary syndrome